“Bimekizumab cumulative clinical benefit in patients with moderate to severe hidradenitis suppurativa through 1 year of the BE HEARD I&II phase 3 trials”, J of Skin, vol. 8, no. 6, p. s477, Nov. 2024, doi: 10.25251/skin.8.supp.477.